Adverse Effects of Senergy OD
The incidence of adverse effects associated with Senergy-OD (Loratadine) tablets and suspension is comparable to placebo in the clinical trials. Headache, fatigue and sedation are reported very rarely.
Contraindications
Patients with known hypersensitivity or idiosyncracy to the drug or to any of its components.
Precautions
Patients with severe liver impairment should be given a lower initial dose due to reduced clearance of Loratadine, an initial dose of 5 mg once daily or 10 mg on alternate day is recommended.
Safety and efficacy of Loratadine in children less than 2 years of age is not established.
There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Loratadine tablets and suspension should be used during pregnancy only if clearly needed. Loratadine is excreted in human milk, hence the expected benefits should be weighed against the possible adverse effects in the infant.
Drug Interactions
- Senergy-OD does not potentiate the effects of alcohol
- Senergy-OD should be discontinued approximately 48 hours prior to skin testing procedures since antihistamines may interfere with and diminish otherwise positive reactions to dermal reactivity indicators
